DDIT3 and plasma cell myeloma: Narita et al. showed that among 2 multiple myeloma cell lines and 6 primary samples, bortezomib treatment resulted in inconsistent protein induction of ATF4, DDIT3 and pro-apoptotic PMAIP1/NOXA but consistent ATF3 protein induction (Narita et al., 2015).